DCC-3116 is under clinical development by Deciphera Pharmaceuticals and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how DCC-3116’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DCC-3116 is under development for the treatment of mutated RAS and RAF mutant advanced or metastatic solid tumors including pancreatic ductal adenocarcinoma, non-small cell lung cancer, colorectal cancer and melanoma. The drug candidate acts by targeting ULK1/2 and is developed based on switch control inhibitor platform. It is administered orally as a tablet.
Deciphera Pharmaceuticals overview
Deciphera Pharmaceuticals is a research and development company that develops, designs, and commercializes kinase inhibiting drugs. The company provides clinical pipeline of kinase inhibitors such as tumor-targeted therapies and immuno-targeted therapies. It uses proprietary switch control inhibitor platform for discovering and developing kinase inhibitors. Deciphera Pharmaceuticals products are used in the treatment of renal and colon cancers, mastocytosis, gastrointestinal stromal tumors, crohn’s disease and autoimmune nephritis, solid tumors and rheumatoid arthritis. The company’s products are used in the treatment of immunological diseases and cancers. It markets its products through medical representatives. Deciphera Pharmaceuticals is headquartered in Waltham, Massachusetts, the US
For a complete picture of DCC-3116’s drug-specific PTSR and LoA scores, buy the report here.